NCT01467141View on ClinicalTrials.gov

Safety and Efficacy of Insulin Aspart in Children With Type 1 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

June 19, 2002

Primary Completion Date

October 15, 2003

Study Completion Date

October 15, 2003

Conditions
DiabetesDiabetes Mellitus, Type 1
Interventions
DRUG

insulin aspart

Injected s.c. (under the skin) three times a day

DRUG

human insulin

Injected s.c. (under the skin) 30 minutes before the meals

DRUG

isophane human insulin

May be administered s.c. (under the skin) in both treatment groups thrice daily

Trial Locations (6)

13353

Novo Nordisk Investigational Site, Berlin

22149

Novo Nordisk Investigational Site, Hamburg

30173

Novo Nordisk Investigational Site, Hanover

49082

Novo Nordisk Investigational Site, Osnabrück

58095

Novo Nordisk Investigational Site, Hagen

01307

Novo Nordisk Investigational Site, Dresden

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT01467141 - Safety and Efficacy of Insulin Aspart in Children With Type 1 Diabetes | Biotech Hunter | Biotech Hunter